Uketa Shoko, Shimizu Yosuke, Ogawa Kosuke, Utsunomiya Noriaki, Katsushima Hironori, Ishihara Misa, Hashimoto Kimio, Kanamaru Sojun
The Department of Urology, Kobe City Nishi-Kobe Medical Center.
The Department of Pathology, Kobe City Nishi-Kobe Medical Center.
Hinyokika Kiyo. 2019 May;65(5):175-179. doi: 10.14989/ActaUrolJap_65_5_175.
Peritoneal metastasis of prostate cancer is extremely rare, with only a few cases reported. A 78-yearold male patient was introduced to our hospital presenting with a prostate-specific antigen (PSA) level of 94.0 ng/ml at examination. He was diagnosed with poorly differentiated adenocarcinoma of the prostate, with a Gleasonscore of 9 (5＋4) at cT3bN0M0. Intensity-modulated radiation therapy was performed after 6 months of combined-androgen blockade (CAB) therapy. Twenty-one months later, several lymph node metastases were observed. With the resumptionof CAB therapy, PSA levels dropped and the multiple lymph node metastasis disappeared ; however, peritoneal metastasis was observed after 43 months. We performed a laparoscopic biopsy and our diagnosis after pathological evaluation was metastasis of the prostate cancer. He was treated with Enzalutamide.
前列腺癌的腹膜转移极为罕见，仅有少数病例报道。一名78岁男性患者因检查时前列腺特异性抗原（PSA）水平为94.0 ng/ml而被收治入院。他被诊断为前列腺低分化腺癌，cT3bN0M0期，Gleason评分9分（5＋4）。在进行6个月的联合雄激素阻断（CAB）治疗后，实施了调强放射治疗。21个月后，观察到多处淋巴结转移。随着CAB治疗的恢复，PSA水平下降，多处淋巴结转移消失；然而，43个月后观察到腹膜转移。我们进行了腹腔镜活检，病理评估后诊断为前列腺癌转移。他接受了恩杂鲁胺治疗。
